FibroGen (FibroGen) FCF Margin % : -106.11% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is FibroGen FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. FibroGen's Free Cash Flow for the three months ended in Mar. 2024 was $-59.3 Mil. FibroGen's Revenue for the three months ended in Mar. 2024 was $55.9 Mil. Therefore, FibroGen's FCF Margin % for the quarter that ended in Mar. 2024 was -106.11%.

As of today, FibroGen's current FCF Yield % is -217.42%.

The historical rank and industry rank for FibroGen's FCF Margin % or its related term are showing as below:

FGEN' s FCF Margin % Range Over the Past 10 Years
Min: -214.91 Med: -36.22 Max: 44.02
Current: -163.99

During the past 12 years, the highest FCF Margin % of FibroGen was 44.02%. The lowest was -214.91%. And the median was -36.22%.

FGEN's FCF Margin % is ranked worse than
52.12% of 1040 companies
in the Biotechnology industry
Industry Median: -141.08 vs FGEN: -163.99

FibroGen FCF Margin % Historical Data

The historical data trend for FibroGen's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen FCF Margin % Chart

FibroGen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-32.92

44.02

-47.77

-131.22

-214.91

FibroGen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-282.58	-251.73	-212.34	-68.44	-106.11

Competitive Comparison of FibroGen's FCF Margin %

For the Biotechnology subindustry, FibroGen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FibroGen's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's FCF Margin % distribution charts can be found below:

* The bar in red indicates where FibroGen's FCF Margin % falls into.

FibroGen FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

FibroGen's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-317.54	/	147.752
	=	-214.91 %

FibroGen's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-59.317	/	55.902
	=	-106.11 %

FibroGen FCF Margin % Related Terms

Thank you for viewing the detailed overview of FibroGen's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroGen (FibroGen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

FGEN:Mexico 1FG:Germany 1FG:Germany

Address

409 Illinois Street, San Francisco, CA, USA, 94158

Website

https://www.fibrogen.com

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Executives

Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno	director, officer: Chief Executive Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig	officer: Chief Commercial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung	officer: SVP, China Operations	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards	director	2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug	director	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck	director	C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner	officer: Incoming Chief Medical Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham	officer: Chief Financial Officer	C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr	director	P O BOX 587, WARSAW IN 46581-0587
Pat Controneo	officer: VP, Finance and CFO	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi	director	C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158